HIV 1 News and Research

RSS

Organ transplant deaths investigated

Three women died within one week of each other after they received diseased organs in transplant procedures at the Austin and Royal Melbourne hospitals according to an ongoing inquest.

3 Mar 2011

Clinton defends State Department budget requests before House panel

In her testimony before the House Foreign Affairs Committee on Tuesday about President Barack Obama's FY12 budget request, Secretary of State Hillary Rodham Clinton also defended the State Department's FY11 budget request, Bloomberg reports. Clinton said the proposed budget cuts for FY11 would be "devastating" to U.S. national security, and U.S. programs in Afghanistan, Pakistan and Iraq would see "sharp reductions" if the proposed cuts are passed.

3 Mar 2011

'Implementation science' approach to play a critical role in next phase of PEPFAR program

An "implementation science" approach will play a critical role in the next phase of The U.S. President's Emergency Plan for AIDS Relief, according to an editorial in JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

GHI executive director addresses global health community at Kaiser Family Foundation town hall

In her first public address since being tapped in January to serve as executive director of President Barack Obama's Global Health Initiative, Lois Quam on Tuesday said she's been doing "a lot of listening" to officials at the State Department, PEPFAR, CDC and other agencies about the GHI.

3 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Adherence counseling during HIV treatment greatly improves patient outcomes

Intensive adherence counseling around the time of HIV treatment initiation significantly reduces poor adherence and virologic treatment failure in sub-Saharan Africa, according to a recent study in PLoS Medicine by Dr. Michael Chung, assistant professor of Global Health at University of Washington, who works at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya.

3 Mar 2011

Study demonstrates neuronal loss during initial stages of HIV infection in mouse model

A new mouse model closely resembles how the human body reacts to early HIV infection and is shedding light on nerve cell damage related to the disease, according to researchers funded by the National Institutes of Health.

3 Mar 2011

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

The Translational Health Sciences and Technology Institute, an autonomous institute of the Indian government's Department of Biotechnology, and the International AIDS Vaccine Initiative announced today an agreement to jointly establish, operate and fund an HIV Vaccine Design Program in India.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Inter Press Service explores how Kenya's Anti-Counterfeit Act, possible EU-India free trade agreement could scale back access to affordable medications

Inter Press Service examines how legislation in Kenya targeting counterfeit medications and a possible EU-India Free Trade Agreement could scale back access to affordable and safe generic medications widely used in developing countries.

2 Mar 2011

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.

2 Mar 2011

New insight into HIV/AIDS

A paper published in the March 2011 print edition of the Journal of Clinical Investigation offers new insight into what prompts immunity to AIDS in sooty mangabeys, a natural host African monkey species.

2 Mar 2011

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

An AIDS vaccine tested in people, but found to be ineffective, influenced the genetic makeup of the virus that slipped past. The findings suggest new ideas for developing HIV vaccines.

2 Mar 2011

HIV women take photos to document their lives

A picture may be worth a thousand words, but for women living with human immunodeficiency virus, the virus that causes AIDS, a picture can help them deal with the challenges of living with the virus.

1 Mar 2011

World’s largest gay media co. partners on cross-cutting HIV/AIDS campaign

Here Media, the world’s largest gay media company, has joined with Greater Than AIDS -- a new national movement to respond to AIDS in America -- to inform and engage the LGBT community about HIV/AIDS. The multimedia partnership includes public service announcements (PSAs) and expanded HIV/AIDS news and editorial across Here Media’s iconic brands -- including Gay.com, OUT, The Advocate, HIV Plus, and MPOWRPlus.com. A dedicated new web portal, http://www.gay.com/greaterthan, provides targeted information and resources for gay and bisexual men.

1 Mar 2011

Tenofovir gel more effective than oral tablet for HIV treatment: Study

In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir - two promising approaches for preventing HIV in women - researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.

1 Mar 2011

Star-Ledger examines Tibotec's agreement with generic drug makers on experimental HIV/AIDS treatment

In a piece on the move by drug manufacturer Tibotec Pharmaceuticals to grant licenses to generic manufacturers in India and South Africa to create copies of its experimental HIV/AIDS drug, the New Jersey Star-Ledger examines why drug companies are particularly focused on expanding their reach in sub-Saharan Africa.

1 Mar 2011

HIV 1 News and Research

Organ transplant deaths investigated

Clinton defends State Department budget requests before House panel

'Implementation science' approach to play a critical role in next phase of PEPFAR program

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

GHI executive director addresses global health community at Kaiser Family Foundation town hall

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Adherence counseling during HIV treatment greatly improves patient outcomes

Study demonstrates neuronal loss during initial stages of HIV infection in mouse model

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Viruses that are natural part of human genome may retrovirus culprit

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Inter Press Service explores how Kenya's Anti-Counterfeit Act, possible EU-India free trade agreement could scale back access to affordable medications

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

New insight into HIV/AIDS

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

HIV women take photos to document their lives

World’s largest gay media co. partners on cross-cutting HIV/AIDS campaign

Tenofovir gel more effective than oral tablet for HIV treatment: Study

Star-Ledger examines Tibotec's agreement with generic drug makers on experimental HIV/AIDS treatment

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News